Our Tests


Also known as: IGH/MYC FISH t(8;14) FISH

« Back to test list


Gene fusions involving the IGH gene at 14q32 and MYC at 8q24 are common in Burkitt lymphoma. They can also occur in other B-cell non-Hodgkin lymphomas, for example, diffuse large B-cell lymphoma (DLBCL). Less commonly, MYC can be fused with other gene partners, such as IGK and IGL.

Such gene fusions have diagnostic and prognostic implications.

Clinical Utility

Presence of an IGH-MYC gene fusion can be useful in diagnosing Burkitt lymphoma. In association with BCL2 and BLC6 gene fusions (see ‘double/triple hit lymphoma panel’), this fusion can also indicate prognosis in B-cell lymphoma with features intermediate between DLBCL and Burkitt lymphoma.

This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.

Test Method

Fluorescent in situ hybridisation (FISH) analysis, using probes to identify fusion of IGH with MYC, due to a t(8;14)(q24;q32) translocation.

Test Ordering

This test is usually requested by a haematologist or oncologist.

0.5 mL bone marrow in transport media, or 5-10 mL blood in lithium heparin.

To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.

We also recommend that the patient or another adult check the labelling of request forms and sample tubes.


Pricing note:

The price varies according to the specific clinical conditions for a particular patient. Please contact Sonic Genetics on 1800 010 447 for more information.

Medicare Rebate

This test is not rebated by Medicare. The laboratory assumes that the patient or client has provided informed financial consent for the test.

Turnaround Time

2 working days.

For Doctors